TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03570710
Drug: intravenous tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
Study: NCT03570710
Drug: Topical tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
Study: NCT01715324
Drug: Adjuvant Growth Hormon
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
Study: NCT02583594
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02583594
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02583594
Drug: alemtuzumab GZ402673
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT02583594
Drug: alemtuzumab GZ402673
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:injection Route of administration: subcutaneous
Study: NCT02583594
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02583594
Drug: Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02583594
Drug: Dexchlorpheniramine
Normalized name: Dexchlorpheniramine
DrugBank: Dexchlorpheniramine maleate (DB09555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00426413
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
Study: NCT00331097
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
Study: NCT00331097
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 intravenously days 1 and 8 every 28 days
Study: NCT00165477
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
Study: NCT01534702
Drug: clofarabine, cytarabine, idarubicin
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1.
Study: NCT01527097
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
Study: NCT01527097
Drug: Atorvastatin placebo
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
Study: NCT00914316
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine, 1000 mg, capsule, twice daily, by mouth.
Study: NCT00543413
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 20 mg tablet once daily. 4 week treatment period.
Study: NCT01737437
Drug: group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline was applied to trachea and laryngoscope blade
Study: NCT01737437
Drug: group V
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
Study: NCT03723772
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
Study: NCT01065987
Drug: Tizanidine
Normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine HCl Tablets 4 mg
Study: NCT00355966
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
Study: NCT00355966
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
Study: NCT03733379
Drug: Metronidazole and Amoxicillin placebos
Normalized name: metronidazole and diloxanide
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
Study: NCT03733379
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
Study: NCT03733379
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
Study: NCT02345902
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: haloperidol 1.25 mg P.O q.d
Study: NCT02504099
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study: NCT02504099
Drug: ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir
Study: NCT02504099
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT02444767
Drug: 13mg Bimatoprost Ocular Insert
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 13mg Bimatoprost Ocular Insert in each eye.
Study: NCT03961932
Drug: Linzagolix
Normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study: NCT01917149
Drug: Benazepril
Normalized name: Benazepril
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01917149
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01917149
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03166891
Drug: Chiauranib
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 50mg orally once daily
Study: NCT01757795
Drug: SP-8203
Normalized name: SP-8203
DrugBank: SP-8203 (DB11670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
Study: NCT01022528
Drug: Dexamethasone (0.1 mg/kg)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02391194
Drug: AVB-620
Normalized name: AVB-101
DrugBank: AVB-101 (DB18416)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01961765
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00730366
Drug: sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
Study: NCT01022528
Drug: Dexamethasone (0.2 mg/kg)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00730366
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
Study: NCT02777866
Drug: Infiltration of 0.5% Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
Study: NCT03329638
Drug: DE-127 Ophthalmic Solution low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Study: NCT03329638
Drug: DE-127 Ophthalmic Solution medium dose
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Study: NCT03329638
Drug: DE-127 Ophthalmic Solution high dose
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Study: NCT02253849
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02253849
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00220285
Drug: Zevalin (SH L 749 , BAY86-5128)
Normalized name: Glutathione-SH
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0,3mCi/kg
Study: NCT02253849
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00220285
Drug: Zevalin (SH L 749 , BAY86-5128)
Normalized name: Glutathione-SH
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0,4mCi/kg
Study: NCT00602472
Drug: linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: active
Study: NCT02345993
Drug: Extra fine Formoterol/Beclomethasone
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes
Study: NCT04446104
Drug: Hydroxychloroquine Sulfate Tablets
Normalized name: Hydroxychloroquine Sulfate Tablets
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
Study: NCT04446104
Drug: Ivermectin 3mg Tab
Normalized name: IVERMECTIN 3MG TAB
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin tablet 12mg single dose
Study: NCT04446104
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine throat spray (3 times daily) for 42 days
Study: NCT01938716
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
Study: NCT00031317
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00031317
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01908803
Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIPRODEX®
Study: NCT04412629
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
Study: NCT03187392
Drug: Lidocaine Injectable Product
Normalized name: lidocaine Injectable Product
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
Study: NCT03187392
Drug: Lidocaine Topical Cream [LMX]
Normalized name: lidocaine Topical Cream [LMX]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
Study: NCT00193544
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00193544
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04424264
Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)
Study: NCT04424264
Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)
Study: NCT04424264
Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg \>70kg
Study: NCT01443676
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be added to radiotherapy
Study: NCT04012957
Drug: Desidustat Oral Tablet
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat tablet
Study: NCT04012957
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin injection
Study: NCT01502774
Drug: Injection of Cyclosporin
Normalized name: cyclosporine Injection
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single intravenous bolus injection of 2.5 mg/Kg
Study: NCT02215252
Drug: PF-05089771 150 mg
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Study: NCT02215252
Drug: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
Normalized name: pregabalin 150 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Study: NCT02215252
Drug: Pregabalin 300 mg
Normalized name: pregabalin 300 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Study: NCT02215252
Drug: PF-05089771 150 mg + Pregabalin 300 mg
Normalized name: pregabalin 150 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
Study: NCT00779350
Drug: sertraline 100 mg tablets
Normalized name: sertraline 100 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00892099
Drug: Ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50,000 IU tablet given weekly
Study: NCT00892099
Drug: Ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50,000 IU tablet given monthly
Study: NCT00811915
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml
Study: NCT01291732
Drug: BI 135585 XX
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of low, medium or high dose of BI 135585 XX
Study: NCT00885170
Drug: Odanacatib
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg tablets once weekly for 24 months
Study: NCT02282098
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6mg twice daily
Study: NCT01371357
Drug: TEST 2
Normalized name: Methitest 25mg Tablet
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study: NCT02590224
Drug: Ferrous bis-glycinate
Normalized name: ferrous bis-glycinate HCl
DrugBank: Ferrous bisglycinate (DB11210)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02590224
Drug: Ferrous glycine sulphate
Normalized name: Ferrous glycine sulphate
DrugBank: Ferrous glycine sulfate (DB14501)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01230983
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01230983
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01230983
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01230983
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01230983
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03033095
Drug: Etanercept ® 50 mg
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
Study: NCT02832115
Drug: Topical Nitroglycerine
Normalized name: nitroglycerin Topical Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
Study: NCT02832115
Drug: Topical Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms